Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2022

Investments, Debt and Equity Securities [Abstract]

The following table summarizes, by major security type, our cash, cash equivalents, restricted cash, and marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in millions):


	December 31, 2021		June 30, 2022
	Total Estimated Fair Value		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Total Estimated Fair Value
Cash	$	10,942	$	9,825	$	—	$	—	$	9,825
Level 1 securities:
Money market funds	20,312		18,816		—		—		18,816
Equity securities (1)(3)	1,646								4,946
Level 2 securities:
Foreign government and agency securities	181		50		—		(1)		49
U.S. government and agency securities	4,300		2,344		—		(122)		2,222
Corporate debt securities	35,764		21,756		—		(673)		21,083
Asset-backed securities	6,738		3,736		—		(164)		3,572
Other fixed income securities	686		407		—		(18)		389
Equity securities (1)(3)	15,740								30
	$	96,309	$	56,934	$	—	$	(978)	$	60,932
Less: Restricted cash, cash equivalents, and marketable securities (2)	(260)								(222)
Total cash, cash equivalents, and marketable securities	$	96,049							$	60,710

___________________

(1)The related unrealized gain (loss) recorded in “Other income (expense), net” was $119 million and $(4.2) billion in Q2 2021 and Q2 2022, and $122 million and $(12.3) billion for the six months ended June 30, 2021 and 2022.

(2)We are required to pledge or otherwise restrict a portion of our cash, cash equivalents, and marketable fixed income securities primarily as collateral for real estate, amounts due to third-party sellers in certain jurisdictions, debt, and standby and trade letters of credit. We classify cash, cash equivalents, and marketable fixed income securities with use restrictions of less than twelve months as “Accounts receivable, net and other” and of twelve months or longer as non-current “Other assets” on our consolidated balance sheets. See “Note 4 — Commitments and Contingencies.”

(3)Our equity investment in Rivian had a fair value of $15.6 billion and $4.1 billion as of December 31, 2021 and June 30, 2022, respectively. The investment was subject to regulatory sales restrictions resulting in a discount for lack of marketability of approximately $800 million as of December 31, 2021, which expired in Q1 2022.

Investments Classified by Contractual Maturity Date

The following table summarizes the remaining contractual maturities of our cash equivalents and marketable fixed income securities as of June 30, 2022 (in millions):


	Amortized Cost		Estimated Fair Value
Due within one year	$	29,370	$	29,344
Due after one year through five years	14,776		13,967
Due after five years through ten years	796		760
Due after ten years	2,167		2,060
Total	$	47,109	$	46,131

Consolidated Statements of Cash Flow Reconciliation - Cash and Cash Equivalents

The following table provides a reconciliation of the amount of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):


	December 31, 2021		June 30, 2022
Cash and cash equivalents	$	36,220	$	37,478
Restricted cash included in accounts receivable, net and other	242		207
Restricted cash included in other assets	15		15
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows	$	36,477	$	37,700

Consolidated Statements of Cash Flow Reconciliation - Restricted Cash


	December 31, 2021		June 30, 2022
Cash and cash equivalents	$	36,220	$	37,478
Restricted cash included in accounts receivable, net and other	242		207
Restricted cash included in other assets	15		15
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows	$	36,477	$	37,700